These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 7880189)

  • 21. Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis.
    Lin AT; Clements PJ; Furst DE
    Rheum Dis Clin North Am; 2003 May; 29(2):409-26. PubMed ID: 12841302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of skin involvement in systemic sclerosis.
    Kumánovics G; Péntek M; Bae S; Opris D; Khanna D; Furst DE; Czirják L
    Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v53-v66. PubMed ID: 28992173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
    Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
    Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo.
    Clements P; Lachenbruch P; Furst D; Paulus H
    Arthritis Rheum; 1993 Nov; 36(11):1575-9. PubMed ID: 8240434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Practical approach to the therapy of systemic sclerosis.
    Czirják L
    Z Rheumatol; 2004 Dec; 63(6):451-6. PubMed ID: 15605208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis.
    Furst DE; Braun-Moscovic Y; Khanna D
    Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v4-v11. PubMed ID: 28992166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis.
    Khanna D; Huang S; Lin CJF; Spino C
    Ann Rheum Dis; 2021 May; 80(5):641-650. PubMed ID: 33257497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of methodological issues of clinical trials in multiple sclerosis.
    Montalban X
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S35-42. PubMed ID: 22206765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies.
    Fallet B; Walker UA
    Expert Rev Clin Pharmacol; 2020 Nov; 13(11):1203-1218. PubMed ID: 33008265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
    Drugs R D; 2007; 8(2):103-12. PubMed ID: 17324008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hematopoietic stem cell transplantation for systemic sclerosis: history and current status.
    Burt RK; Milanetti F
    Curr Opin Rheumatol; 2011 Nov; 23(6):519-29. PubMed ID: 21857226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Phases 0, 1 and 2 oncology clinical trials: current questions].
    Penel N; Fournier C; Stéphanie C
    Bull Cancer; 2010 Jan; 97(1):55-63. PubMed ID: 20080458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interstitial lung disease points to consider for clinical trials in systemic sclerosis.
    Khanna D; Seibold J; Goldin J; Tashkin DP; Furst DE; Wells A
    Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v27-v32. PubMed ID: 28992174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma.
    Hulshof MM; Bouwes Bavinck JN; Bergman W; Masclee AA; Heickendorff L; Breedveld FC; Dijkmans BA
    J Am Acad Dermatol; 2000 Dec; 43(6):1017-23. PubMed ID: 11100017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adaptive phase I/II clinical trials for drug combination assessment in oncology using the outcomes of each cycle.
    Yada S; Hamada C
    Pharm Stat; 2017 Nov; 16(6):433-444. PubMed ID: 28840635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol.
    Calderone A; Stevens W; Prior D; Nandurkar H; Gabbay E; Proudman SM; Williams T; Celermajer D; Sahhar J; Wong PK; Thakkar V; Dwyer N; Wrobel J; Chin W; Liew D; Staples M; Buchbinder R; Nikpour M
    BMJ Open; 2016 Dec; 6(12):e011028. PubMed ID: 27932335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
    DeMarco PJ; Weisman MH; Seibold JR; Furst DE; Wong WK; Hurwitz EL; Mayes M; White B; Wigley F; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
    Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.